title: Don't multiple drug and other cross resistances in cancer therapy compromise (phase 2) efficacy trials?
authors.forename: G
authors.initials: G
authors.lastname: Mathé
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*